The discovery of diverse chemical modifications of mRNA has spurred efforts to identify, map and characterize them. Yet aside from N6-methyladenosine (m6A), progress in epitranscriptomics has been stymied by discrepant data. Here we discuss the main obstacles in studying novel mRNA modifications and offer insights into how to surmount them.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The role of post-transcriptional modifications during development
Biologia Futura Open Access 08 December 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dominissini, D. et al. The dynamic N 1 -methyladenosine methylome in eukaryotic messenger RNA. Nature 530, 441–446 (2016).
Safra, M. et al. The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature 551, 251–255 (2017).
Zhou, H. et al. Evolution of a reverse transcriptase to map N1-methyladenosine in human messenger RNA. Nat. Methods 16, 1281–1288 (2019).
Zaccara, S., Ries, R. J. & Jaffrey, S. R. Reading, writing and erasing mRNA methylation. Nat. Rev. Mol. Cell Biol. 20, 608–624 (2019).
Sas-Chen, A. et al. Dynamic RNA acetylation revealed by quantitative cross-evolutionary mapping. Nature 583, 638–643 (2020).
Shi, H., Wei, J. & He, C. Where, when and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol. Cell 74, 640–650 (2019).
Delatte, B. et al. Transcriptome-wide distribution and function of RNA hydroxymethylcytosine. Science 351, 282–285 (2016).
Su, R. et al. R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling. Cell 172, 90–105 (2018).
Barbieri, I. & Kouzarides, T. Role of RNA modifications in cancer. Nat. Rev. Cancer 20, 303–322 (2020).
Yankova, E. et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593, 597–601 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.F. is a co-founder of EPICS Therapeutics (Gosselies, Belgium). The remaining authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Penning, A., Jeschke, J. & Fuks, F. Why novel mRNA modifications are so challenging and what we can do about it. Nat Rev Mol Cell Biol 23, 385–386 (2022). https://doi.org/10.1038/s41580-022-00485-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41580-022-00485-8
This article is cited by
-
The role of post-transcriptional modifications during development
Biologia Futura (2023)